Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

被引：0

作者：

Craig Leonardi

Kristian Reich

Peter Foley

Hideshi Torii

Sascha Gerdes

Lyn Guenther

Melinda Gooderham

Laura K. Ferris

Christopher E. M. Griffiths

Hany ElMaraghy

Heidi Crane

Himanshu Patel

Russel Burge

Gaia Gallo

David Shrom

Ann Leung

Chen-Yen Lin

Kim Papp

机构：

[1] Central Dermatology,Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing

[2] University Medical Center Hamburg-Eppendorf,St. Vincent’s Hospital Melbourne and Probity Medical Research, Skin Health Institute

[3] Skinflammation® Center,Division of Dermatology

[4] The University of Melbourne,Psoriasis

[5] Tokyo Yamate Medical Center,Center at the Department of Dermatology

[6] University Medical Center Schleswig-Holstein,Dermatology Centre, Salford Royal Hospital

[7] Guenther Dermatology Research Centre,undefined

[8] SkiN Centre for Dermatology and Probity Medical Research,undefined

[9] University of Pittsburgh Medical Center,undefined

[10] University of Manchester,undefined

[11] Eli Lilly and Company,undefined

[12] Lilly Corporate Center,undefined

[13] Syneos Health,undefined

[14] K. Papp Clinical Research and Probity Medical Research Inc.,undefined

来源：

Dermatology and Therapy | 2020年 / 10卷

关键词：

Ixekizumab; Long-term efficacy; Long-term safety; Maintain; Psoriasis; Quality of life; 5 years;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：431 / 447

页数：16

共 50 条

[1] Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials
Leonardi, Craig
Reich, Kristian
Foley, Peter
Torii, Hideshi
Gerdes, Sascha
Guenther, Lyn
Gooderham, Melinda
Ferris, Laura K.
Griffiths, Christopher E. M.
ElMaraghy, Hany
Crane, Heidi
Patel, Himanshu
Burge, Russel
Gallo, Gaia
Shrom, David
Leung, Ann
Lin, Chen-Yen
Papp, Kim
DERMATOLOGY AND THERAPY, 2020, 10 (03) : 431 - 447
[2] Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)
Reich, Kristian
Leonardi, Craig
Lebwohl, Mark
Kerdel, Francisco
Okubo, Yukari
Romiti, Ricardo
Goldblum, Orin
Dennehy, Ellen B.
Kerr, Lisa
Sofen, Howard
JOURNAL OF DERMATOLOGICAL TREATMENT, 2017, 28 (04) : 282 - 287
[3] Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3
Egeberg, Alexander
Wu, Jashin J.
Korman, Neil
Solomon, James A.
Goldblum, Orin
Zhao, Fangyi
Mallbris, Lotus
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (01) : 104 - +
[4] Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
Griffiths, Christopher E. M.
Reich, Kristian
Lebwohl, Mark
van de Kerkhof, Peter
Paul, Carle
Menter, Alan
Cameron, Gregory S.
Erickson, Janelle
Zhang, Lu
Secrest, Roberta J.
Ball, Susan
Braun, Daniel K.
Osuntokun, Olawale O.
Heffernan, Michael P.
Nickoloff, Brian J.
Papp, Kim
LANCET, 2015, 386 (9993): : 541 - 551
[5] Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1)
Imafuku, Shinichi
Torisu-Itakura, Hitoe
Nishikawa, Atsushi
Zhao, Fangyi
Cameron, Gregory S.
JOURNAL OF DERMATOLOGY, 2017, 44 (11): : 1285 - 1290
[6] Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)
Blauvelt, Andrew
Gooderham, Melinda
Iversen, Lars
Ball, Susan
Zhang, Lu
Agada, Noah O.
Reich, Kristian
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (05) : 855 - 862
[7] Ixekizumab impact on the skin-related relationship problems of patients with moderate-to-severe plaque psoriasis: integrated results from three Phase 3 trials (UNCOVER-1,-2,-3)
Warren, R. B.
Cather, J.
Ohtsuki, M.
Bleakman, A. Potts
Burge, R.
Zhu, B.
Reich, K.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 77 - 78
[8] Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2)
Papp, Kim A.
Gerdes, Sascha
Leonardi, Craig L.
Elmaraghy, Hany
See, Kyoungah
McKean-Matthews, Missy
Konicek, Bruce W.
Crane, Heidi M.
Eastman, William
JOURNAL OF DRUGS IN DERMATOLOGY, 2021, 20 (08) : 880 - 887
[9] Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3
Kemeny, Lajos
Berggren, Lovisa
Dossenbach, Martin
Dutronc, Yves
Paul, Carle
JOURNAL OF DERMATOLOGICAL TREATMENT, 2019, 30 (01) : 19 - 26
[10] Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes
Puig, Luis
Dossenbach, Martin
Berggren, Lovisa
Ljungberg, Anders
Zachariae, Claus
ACTA DERMATO-VENEREOLOGICA, 2019, 99 (11) : 971 - 977

← 1 2 3 4 5 →